ABSTRACT
Numerous biliary proteins as well as non-protein factors influence kinetics of cholesterol crystallisation from supersaturated bile. Cholesterol crystallisation pathways, methods used for quantitative evaluation of liquid-to-solid transition of cholesterol in bile and the classical concept of nucleation defect in pathogenesis of gallstones are reviewed in the first part of this article. The relevance of individual biliary proteins and non-protein factors is discussed in the second part. Finally, a new concept according to which accelerated crystallisation of cholesterol inhibits gallstone growth and protects the gallbladder wall from toxic injury resulting from the increased absorption and accumulation of cholesterol from supersaturated bile is suggested.
INTRODUCTION
The primary event on the way from gallstone free bile to cholesterol gallstones is supersaturation of bile with cholesterol. Additional defects appearing simultaneously in patients with cholesterol gallstones are gallbladder hypomotility, accelerated cholesterol crystallisation in bile and mucus hypersecretion. These additional defects may be balanced differentially in patients with solitary stones growing for many years (1, 2) and in patients with multiple small stones.
This review focuses on the role of protein factors influencing kinetics of cholesterol crystallisation in supersaturated bile. Composition of bile, physiology of bile secretion and physical-chemistry of bile are summarised briefly and the reader is referred to numerous recent reviews on these topics.
BILIARY LIPIDS
Bile salts, phospholipids, sterols and lipopigments are the major lipid species in bile (3, 4). Changes in their composition exceeding their physiological range are of crucial importance in pathogenesis of all types of gallstones. Biliary lipids are secreted from hepatocytes that are equipped with a series of transport systems (164) . B: Sequence of structures appearing during these pathways. For pathway A, arc-like crystals appear, followed by helices, tubules and plates. For pathway B, plates appear initially, followed by transient appearances of helices, tubules and plates. In pathway C, formation of microscopically observable vesicles precede the same sequence as in B. In pathway D, liquid crystals precede the development of plate. Pathway E denotes regions of the phase diagram where only liquid crystals are present. From ref. (164) . specialised for secretion of many kinds of compounds against a steep concentration gradient (see the recent reviews (5-8)).
Free water insoluble cholesterol (solubility of cholesterol in water is 10 -8 mol/L ) is present in bile in four types of liposomes (lipid aggregates) (3, 9): simple micelles, mixed micelles, unilamellar vesicles and multilamellar vesicles. The type of, the ratio between and the chemical composition of biliary lipid aggregates in their equilibrated water solution are influenced by multiple factors. The most important factors are the total concentrations of bile salts, phospholipids and cholesterol (3, 10-12), the concentrations of individual bile salts (13) and the degree of saturation of biliary phospholipids (14-16).
Phase and chemical composition of lipid aggregates have been studied extensively in model systems (17-19) and equilibrium phase diagrams have been constructed. Based on these studies, maximal equilibrium concentrations of cholesterol in the liquid phase were calculated, and the cholesterol saturation index (CSI) was defined to express the saturation rate of the liquid phase (20-22).
Bile is never in equilibrium in vivo. Unilamellar "nascent" vesicles composed of phospholipids and cholesterol are co-secreted with monomeric bile salts into canalicular bile and lipid secretion is followed by postcanalicular formation of micelles. Cholesterol and, to a greater extent, phospholipids are shifted into mixed micelles in the gallbladder (23), and a continuous change in the composition of gallbladder bile is accompanied by rearrangement of biliary liposomes. Biliary liposomes are thought to be the main source of cholesterol excess in bile, supplying the sterol for both crystal formation and gallstone growth.
CHOLESTEROL CRYSTALLISATION IN BILE

Cholesterol crystallisation pathways
A classical description of the cholesterol crystallisation pathway based on the observation of Halpern et al. (24) involves two steps. Aggregation and fusion of vesicles supersaturated with cholesterol leads to formation of liquid crystals and plate-like crystals of cholesterol monohydrate nucleate and grow from liquid crystals. This concept has several weak points:
Firstly, a body of older literature (24-29), as well as several more recent studies (30-32), support the concept that biliary vesicles are the main precursors of newly formed cholesterol crystals. Phospholipid/cholesterol vesicles are enriched with cholesterol during postcanalicular formation of micelles, and, thus, may become the main cholesterol carriers in supersaturated bile. Owing to their size (33), cholesterol nuclei are most likely formed within the layers of vesicles, perhaps in special cholesterol rich domains (34), and then are fed with cholesterol from either vesicles or micelles (32). However, aggregation and/or fusion of vesicles has not been directly visualised in any of the most recent studies.
Secondly, liquid crystals do not always precede formation of solid cholesterol crystals. Classical plates with the missing edge birefringent in polarised light are not the only form of cholesterol crystals because, in some biles, transient forms of non-plate-like filamentous, helical, and tubular crystals of anhydrous cholesterol may appear under certain circumstances. Wang and colleagues (35) described 5 different pathways, named A to E, in their study on model biles (Figure 1 ). Sequences B, C and D have also been observed in native human biles (36). There is no explanation for these phenomena in the classical concept.
Measurement of cholesterol crystallisation in bile
Crystal observation time, inappropriately called nucleation time (NT) as critical cholesterol nuclei are too small to be detected, was the first method used in studies on the early phases of cholesterol crystallisation (45). Bile samples are ultracentrifuged to remove the already present cholesterol crystals, the microscopically isotropic upper phases are incubated at 37 o C, and aliquots are checked every 24 hours by polarisation microscopy for the presence of newly formed crystal(s). It is clear that the point at which cholesterol crystallisation occurs cannot be precisely defined, and this method thus possesses an intrinsic error. In addition, this method is only qualitative, which implicates another possible source of error. Attempts to quantify cholesterol crystallisation have been made, and a number of methods reflecting crystal occurrence as a function of time have been elaborated. Counting the number of crystals in a Burker's chamber in a polarisation microscope is a simple, more reproducible method than nucleation time, but it is also much more laborious. Less laborious but less sensitive turbidimetric assays (37, 38) and nephelometric assays (39) have been used in some studies. The spectrophotometric assay was also modified for use in microtiter plates (40). The weak point of turbidimetry or nephelometry is the assumption that all crystals are of approximately the same size. To overcome this problem, measurement of cholesterol crystal mass obtained by sequential gradient density ultracentrifugation of aliquots was reported as an alternative approach (41). A novel procedure for the measurement of gallstone growth rate has recently been described by van den Berg and coworkers (42). In this procedure, the growth rate is expressed as the change of the mass of multiple small human gallstones originating from the same patient during their incubation in the tested bile.
Kinetics of cholesterol crystallisation
Supersaturation of bile with cholesterol is not sufficient to produce cholesterol gallstones because highly supersaturated bile was found in many gallstone free subjects (43). In a study on Pima Indians, a population with the highest prevalence of cholesterol gallstones, it appeared to take many years to develop gallstones from highly supersaturated bile (44). Holan and co-workers (45) first reported striking differences between cholesterol crystal observation times of gallbladder biles of the same CSI. Crystals occurred over 5 (mean 15) days in biles from gallstone free subjects but in less than 4 days in biles from gallstone patients. No correlation was found between CSI and NT in the gallstone group and rapid nucleation was observed in several gallstone free patients with undersaturated bile. These findings indicated that CSI values calculated for the model system did not reflect completely the situation in native bile. Presence of factors influencing kinetics of cholesterol nucleation was suggested to explain the discrepancy.
Another argument supporting the concept of the role of a nucleation defect in the pathogenesis of gallstones is that nucleation of cholesterol in native bile is heterogenous (46), indicating that additional compound(s) or substance(s) promoting nucleation and/or growth of nuclei over their critical diameter must be involved to accelerate the process. For homogenous nucleation, higher CSI values (>3) have been predicted that are almost never found in native bile (46). Nucleation defects play an important role in a subgroup of patients with multiple gallstones. While solitary gallstones develop over a time period of several years (1, 2, 47) and have been suggested to grow from freefloating crystal plates, formation of multiple stones requires an abrupt crystallisation event (47). Jungst and co-workers (48) found, indeed, that nucleation was faster in patients with multiple gallstones than in those with solitary gallstones.
There have always been arguments against the study of in vitro nucleation in the pathogenesis of gallstone disease. Firstly, it was argued that there is no method to completely remove critical nuclei or undetectable microcrystals of cholesterol from rapidly nucleating bile (49). The question arises why these nuclei or crystals do appear in biles of gallstone patients but do not appear in biles of the same CSI from controls (50-52). Secondly, if cholesterol nuclei are completely removed, measurement of de novo (re)nucleation represents an artificial condition irrelevant to the in vivo situation in which the growth rate of the yet existing crystals seems to be more important (49). Finally, there is the question of whether the nucleation influencing factors are independent of or just induced by supersaturation of bile with cholesterol.
CHOLESTEROL CRYSTALLISATION PROMOTING AND INHIBITING FACTORS
A search for the principal nucleation-promoting factor was started by the observation of Burnstein and colleagues (53) that addition of a small amount (2-10%) of rapidly nucleating bile to a slowly crystallising bile decreased significantly nucleation time of the mixture. The role of a protein factor was postulated by Holzbach et al.
(54), who reported an increase in nucleation time by a mixture of biliary proteins supplemented with biliary lipids. Subsequently, a long list of biliary constituents has been checked for their possible role in the acceleration or inhibition of cholesterol crystallisation.
Non-protein regulators of cholesterol crystallisation
Cholesterol nucleation regulating factors can be divided into three groups:
Firstly, certain parameters of lipid composition of bile such as total lipid concentration, hydrophobicity of bile salts, bile salt/lecithin ratio and cholesterol/lecithin ratio of vesicles have been proven to influence kinetics of cholesterol crystallisation (55).
Secondly, calcium salts, contamination of bile by microorganisms and biliary sludge have been proposed as non-protein regulators of cholesterol crystallisation.
Calcium salts, mostly bilirubinates and phosphates, are regularly found in centres of cholesterol gallstones (56-58), and, together with mucin and other biliary proteins, in concentric shell-like layers (59). Formation of these layers is explained by precipitation of calcium carbonate in an organic matrix, a process similar to biomineralisation seen in other tissues, such as bones and teeth. Low molecular weight biliary calcium-binding proteins, known as APF/CBP (anionic protein fraction/calcium binding protein), have been reported to play a regulatory role in the biomineralisation of cholesterol gallstones (for review, see (60)). Ostrow proposed a hypothesis about the role of both calcium and APF/CBP in cholesterol nucleation, incorporating both the involvement of calcium in the process of formation of the gallstone nidus and the effect of APF/CBP as a regulator of calcium precipitation (57). Indeed, in model biles, APF inhibited cholesterol mass precipitation rate but not cholesterol crystal occurrence time, while calcium had the opposite effect (61). A rapid precipitation of calcium phosphates, seeded in mucin-containing model bile, induced rapid crystallisation of cholesterol (62) . Whether calcium also plays a role in native bile is questionable, because addition of EDTA to native bile did prevent precipitation of calcium bilirubinate but did not influence cholesterol crystal occurrence time (36, 63).
The finding of calcium palmitate in the core of some cholesterol gallstones implicated a potential role of bacteria, in particular Escherichia coli, in the initial phase of cholesterol gallstone disease (64). Swidsinski and colleagues have reported the presence of bacterial DNA in the centres, but not in the peripheries of cholesterol gallstones (65, 66) . Though doubted by some (66, 67) , the presence of bacteria in gallbladder bile in the early phase of stone formation is not unlikely. It can be concluded either that bacteria directly participate in the formation of the nucleus of cholesterol gallstone or that the nidus appears as a consequence of infection or inflammation induced by these bacteria. On the other hand, simultaneous occurrence of both events cannot be excluded.
Biliary sludge represents an amorphous substance composed of crystals of cholesterol monohydrate, calcium salts of unconjugated bilirubin and mucus (68) . Sludge can be visualised by ultrasonography in subjects under different conditions, such as pregnancy (69), rapid weight loss, ceftriaxone therapy, octreotide therapy, bone marrow or solid organ transplantation (70) and, importantly, in patients on long-term parenteral nutrition (71) . It may be a transient phenomenon, but, in a subgroup of individuals, pigment or cholesterol gallstones may occur (72) . Sludge is important for stabilisation of aggregated vesicles and crystals, and it may act as a nidus during formation of the gallstone nucleus (73) .
The third group of cholesterol nucleation regulatory factors is represented by mucin and non-mucin biliary proteins, which are discussed in the following section.
Biliary proteins involved in regulation of cholesterol nucleation and crystal growth 5.2.1. Mucin
Mucin is a highly glycosylated glycoprotein made up of approximately 80% carbohydrate and 20% protein.
Mucin glycans are mostly O-linked, range from 8-20 sugars in length, and consist of neutral sugars which form a backbone to which sialic acid and sulfate esters might be attached at the periphery (74) (75) (76) (77) (78) (79) . All mucins also possess N-glycosylation sites. Nine MUC genes coding different mucin proteins, numbered MUC1 to MUC4, MUC5A, MUC5B, and MUC6 to MUC8, have been reported (77, 80, 81) . The ubiquitously expressed (82) MUC1 is the main membrane-associated and non-gel-forming mucin. MUC5B and MUC3 are the major gel-forming mucins present in the gallbladder (83). Primary structure of MUC5B is organised into a N-terminal, a tandem repeat and a C-terminal domain. The N-terminal domain is composed of three cysteine enriched, poorly-glycosylated, von-Willebrand factor-like D1-D3 domains, containing motifs resembling sequences from adhesion molecules, the LDL receptor, and scavenger receptors (84). The tandem repeat domains contain 7 extensively glycosylated R domains, divided with 7 short cysteine-rich Cys subdomains (85). The C-terminal domain is again less glycosylated and contains a vonWillebrand factor-like D4 domain (86, 87) . The structure of MUC3 is similar, but the cysteine-rich D domains resemble epidermal growth factor motifs (88) (89) (90) . Gel-forming mucins polymerise through intermolecular disulfide linkages between cysteine-rich domains.
The primary function of gallbladder mucin is probably to protect the gallbladder mucosa from chemical or microbial injury (91) . There are several reasons to believe that gallbladder mucin is also involved in early stages of the pathogenesis of cholesterol gallstone disease.
Firstly, as already mentioned in the previous section, mucin is frequently found in core parts of cholesterol gallstone (56).
Secondly, mucin hypersecretion is known to precede the formation of stones in both experimental animals (92-94) and humans (95) fed with cholesterolenriched diet. The stimulus for hypersecretion must be present in bile, because, in prairie dogs fed with a lithogenic diet after cystic duct ligation, no hypersecretion of mucin in the gallbladder could be observed (92) . Prostaglandins and their precursor, arachidonic acid, were the first pro-inflammatory mediators suggested to induce increased secretion of mucin (96-98). Despite these studies, the role of prostaglandins remains controversial, since no effect on mucin secretion was reported by others (99) and, in human clinical studies in which non-steroidal anti-inflammatory drugs were administered to patients on rapid-weight reducing diets (100) or after gallstone dissolution therapy (101) , no reduction of the risk of gallstone development was observed. The influence of other biliary constituents, such as lysophosphatidylcholine (98) , tumour necrosis factor alpha (102, 103) and cholesterol, on mucin secretion has also been studied. Accumulation of cholesterol in gallbladder wall has been shown to decrease membrane fluidity of biliary epithelia and, perhaps, increase generation of NO (83) by induction of inducible NO synthase, which is the principle isoform of NO synthetase expressed in the gallbladder (104) . The role of NO as a mucin secretagogue has been demonstrated in other tissues (83).
Thirdly, mucin forms a gel layer, which serves as a matrix for biliary sludge, described above, in which cholesterol crystals nucleate (73) .
Fourthly, in a number of studies, gallbladder mucin was found to act as promoter of cholesterol crystallisation. This effect appeared to be both time and dose dependent (105, 106) . No differences were found between cholesterol crystallisation activities of mucin purified from gallbladder of gallstone patients and control subjects, suggesting that there was no qualitative difference between the isolated mucin samples (107) . An important property of mucin is its capability to bind biliary lipids (106) and a series of other hydrophobic compounds (108, 109) . This property is lost after treatment of mucin with pronase that destroys selectively poorly glycosylated domains and abolishes its cholesterol crystallisation promoting activity (106). Afdhal and co-workers (110) demonstrated in model biles with fluorescently labeled vesicles that mucins accelerate both vesicle fusion and aggregation. While glycan domains reversibly promoted vesicle aggregation, hydrophobic domains facilitated fusion of vesicles. However the second half of the hypothesis that large multilamellar vesicles generate crystals more rapidly in presence of mucin remained unproven.
Non-mucin proteins in bile and how do they get there
Biliary proteins represent about 4% of biliary solutes by weight (3). The most abundant biliary proteins are albumin, mucin, APF/CBP and IgA.
There are several sources of biliary proteins (111) . The majority of biliary proteins originate from serum. Serum proteins are thought to be secreted into bile via a paracellular pathway across tight junctions between hepatocytes and biliary epithelia (111, 112) . The driving force for this secretion is the concentration gradient. The total protein concentration in hepatic bile is about 50 times lower than in serum. The diffusion rate of individual biliary proteins is inversely proportional to their molecular weight (113) . A significant part of biliary albumin is secreted into bile directly from hepatocytes (114) . The same may be true for other biliary serum derived proteins. Transcytosis is another pathway by which serum proteins can get into bile. This process is started by pinocytosis or receptor-mediated endocytosis of certain proteins at the sinusoidal pole of hepatocytes. Polymeric IgA receptor-mediated endocytosis is a well studied pathway responsible for clearance of serum IgA in rats (115) (116) (117) (118) (119) . A part of the extracellular domain of polymeric IgA receptor, known as secretory component, is cut by a specific protease and remains bound to secreted IgA (120).
A minor part of biliary proteins are canalicular membrane proteins that are either extracted from the canalicular membrane by bile acids or co-secreted into bile with phospholipids (121).
Finally, lysosomal enzymes are secreted into bile via exocytosis (122-124).
Cholesterol crystallisation inhibitors
Since the bile of patients without gallstones was frequently found to be supersaturated with cholesterol, the presence of cholesterol crystallisation inhibitors was expected in such biles. Holzbach et al. (54) found indeed a protein fraction that inhibited cholesterol crystallisation. Apolipoproteins A-I and A-II appeared to be good candidates in model systems (125) . Busch et al. (126) confirmed that Apo A-I both increased the cholesterol crystal occurrence time and reduced the rate of crystal growth. The molecular mechanism of these effects was partially elucidated by Yamashita and co-workers (127, 128) , who observed the interaction of commercially available Apo A-I with vesicles, but not with micelles in model systems. The effect of Apo A-I on cholesterol nucleation and crystal growth was explained as stabilization of the cholesterol-rich vesicles and prevention of their fusion. These findings further supported the conclusions of the earlier sequential transmission electron microscopy study by Tao et al. (129) . To circumvent the objections that all the above listed studies were made either with commercial or partially denatured biliary Apo A-I, Apo A-I was isolated from bile under non-denaturing conditions, its vesicle stabilising effect was confirmed, and a novel function of Apo A-I as promoter of cholesterol absorption in the gallbladder was proposed (130) . However, one argument against the role of apolipoproteins A-I and A-II in cholesterol gallstone formation in vivo still remains: no differences were found between apoprotein concentrations in gallstone patients and controls (131).
Holzbach's group has reported two additional cholesterol crystallisation inhibitors. A 128kDa glycoprotein composed of 58-and 63-kDa subunits was isolated by affinity chromatography using a Helix Pomatia lectin affinity column (132) . A low-molecular (15kDa) biliary protein that forms dimers and tetramers appeared to be capable of inhibiting cholesterol crystallisation (133) . In both studies, the reported proteins were not fully characterised, and no data on their biliary concentrations are available.
Finally, the inhibitory effect of IgA (134) and its components (135) on cholesterol crystal growth has been reported. While the relevance of the earlier study (135) seems to be low, because denaturation of IgA occurred during the isolation procedure, the crystal growth inhibitory effect of biliary IgA was clearly demonstrated in the later study (134) , although only at low (1 and 10 mcg/ml) concentrations. In contrast, others (136, 137) reported an opposite effect of IgA on cholesterol nucleation. The explanation of these controversial findings may be that 
Cholesterol crystallisation promoters
The first evidence for the presence of cholesterol crystallisation promoters in bile has been already mentioned (53). Using lectin affinity chromatography with Concanavalin A (Con A) Sepharose, a non-mucin cholesterol crystallisation-promoting biliary glycoprotein fraction was isolated by Groen et al. (138) . This activity of the Con A-binding biliary glycoproteins was pronaseresistant and specific for biliary glycoproteins, because no 
visible on SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
A number of biliary glycoproteins contained in CABF have been found to possess the cholesterol crystallisation promoting activity (table 1) .
Immunoglobulins IgM and IgG were found to be the most active candidates, shortening crystal detection time in both heat-inactivated bile (136, 140) and model bile (137, 141) . The levels of immunoglobulins in bile were found to be increased in cholesterol gallstone patients (136, 140) , and up to a twelvefold increase was reported in Chilean patients (142) . However, immunoextraction of immunoglobulins from Con A-binding biliary glycoprotein fraction did not influence crystallisation activity (143) . Moreover, immunoglobulins are sensitive to treatment with pronase (139) .
A role for fibronectin as a promoter of cholesterol nucleation was suggested by Chijiiwa et al (144) , but others have not confirmed their results (145) .
The group of Holzbach found cholesterol crystallisation-promoting activity in several acute phase proteins (146, 147) . The concentration of alpha-1-acid glycoprotein was increased in the bile of gallstone patients (148) , and its extraction by immunoaffinity chromatography decreased the activity by 33% (141) . Unfortunately, no effect of immunoextraction of alpha-1-acid glycoprotein from Con A-binding fraction of biliary glycoproteins could be observed (143). (149) found a pronaseresistant C-like phospholipase activity that revealed high cholesterol crystallisation-promoting activity. In opposition to that, no activity of the immunoaffinity purified phospholipase C was detected (141) .
Pattinson and Willis
A set of biliary glycoproteins associated with biliary vesicles has been described by Miquel and coworkers (150, 151) . Beside albumin and immunoglobulins, four hydrophobic glycoproteins, with molecular weights, which were 130, 114, 85 and 62-67kDa on SDS-PAGE gel under non-reducing conditions, were found. Three of them had a significant crystallisation-promoting activity in model bile. The 130kDa glycoprotein was later characterised as aminopeptidase N (152). However, no differences were found in concentration of aminopeptidase N in biles of gallstone patients versus controls, nucleation time correlated only with relative concentrations of aminopeptidase N in the gallstone group (153) and no immunoextraction experiments have been reported to our knowledge.
Finally, Ziljstra and co-workers performed a series of experiments in order to isolate and characterise the pronase-resistant glycoprotein crystallisation promoters from bile (154) . The Con A-binding fraction of biliary glycoproteins was digested with pronase and subsequently fractionated on a superose gel-permeation column. Two peaks, in the void volume and at 60kDa, contained the activity. The 60kDa peak contained a number of fragments derived from the protease inhibitors alpha-1-antitrypsin and alpha-1-antichymotrypsin. The void volume peak contained biliary lipids and an 85kDa protein similar in composition to the so-called low-density lipid-protein particle isolated from the Con A-binding fraction of biliary glycoproteins by de Bruijn et al. (143) . The 85kDa pronase-resistant glycoprotein has recently been identified as the 85kDa isoform of carcinoembryonic antigen-related cell adhesion molecule 1 (155) . Surprisingly, concentrations of total carcinoembryonic antigen (CEA) cross-reacting protein in gallbladder bile were found to be lower in bile of patients with either cholesterol and pigment gallstones than in controls without gallstones who underwent operations for pancreatic cancer, ampullomas and chronic pancreatitis (156) . When biliary CEA cross-reacting proteins were fractionated by SDS-PAGE and their relative concentrations were measured densitometrically on immunoblots, two isoforms of CEA-related cell adhesion molecule 1 (115 and 85kDa, respectively) and two, as-yet unreported CEA cross-reacting proteins of MW 40 and 50kDa were found. The increase of these proteins, specifically of the 50kDa protein, could partially explain the difference in total CEA cross-reacting protein in gallstone and non-gallstone patients.
RELEVANCE OF PRO-AND ANTI-NUCLEATING FACTORS
To evaluate the role of individual biliary proteins in this process, Harvey and Strasberg (157) formulated criteria that must be met by any substance functioning as promoter of cholesterol nucleation: (a) the substance should be present in fast-crystallising bile with either a quantitative or qualitative difference from normal bile; (b) upon extraction of the substance from fast-crystallising bile, the crystallisation should be delayed; and (c) when the substance is added to slowly crystallising bile, the crystallisation should be accelerated. A fourth criterion that applied specifically to proteins was added by van den Berg and Groen (42): (d) the protein must be resistant to digestion with pronase.
The first criterion, a difference in concentration or quality of protein, has never been tested strictly, for ethical reasons. The only proteins that have been checked against the remaining criteria and have been subjected to all available tests are biliary mucin and IgG. Although these proteins clearly stimulated crystallisation in model systems, extraction from native bile failed to inhibit crystallisation (107, 142) . In addition, the promoting activity of both proteins was sensitive to pronase digestion (154) . Keulemans et al. (158) demonstrated that extraction of the combined Con A-binding fraction in bile does decrease crystallisation strongly in biles from patients with rapidly crystallising biles. Addition of this fraction has been shown to stimulate crystallisation in native bile (138) , and the activity was absent in biles from control patients (159) . In addition, the activity was fully resistant to pronase.
Despite intensive research, the individual factors responsible for this activity have not been fully identified. Potential candidates are alpha-1-antichymotrypsin, phospholipase C-like activity and a CEACAM1-85-containing low density particle. Since the concentarions of these factors did not differ significantly between biles from stone patients and controls, the quantity is probably not the discriminating factor. Whether the quality is different remains to be established. It can also not be excluded that the promoting activity is the result of an interaction between the different factors.
It has generally been assumed that accelerated crystallisation of cholesterol in bile plays an imporatnt role in cholesterol stone formation. The recent work of van den Berg et al. (160) has shed a different light on this paradigm. In studies on regulation of gallstone growth, promoters were found to inhibit crystallisation on the stone surface, probably because the accelerated crystallisation in the aqueous phase rapidly reduces cholesterol supersaturaion. Apparently, crystallisation on the stone surface and crystallisation in the aqueous phase are two independent processes that compete for the excess cholesterol present in bile. Supersaturated bile has been shown to be toxic to the gallbladder (161) . Stone formation and production of crystallisation promoters may be a response of the gallbladder to dispose of the toxic agent. Irritation of the galbladder wall by supersaturated bile may induce local (insoluble) mucin hypersecretion which provides a nidus on which excess cholesterol can readily crystallise. A subsequent production of cholesterol crystallisation promoters may represent an additional response of the liver and/or gallbladder to cholesterol supersaturated bile. By stimulating precipitation of cholesterol in the aqueous phase, deposition in the gallbladder wall or in stones is prevented. The crystallised cholesterol is probably not reabsorbed, and such a mechanism would serve to efficiently remove cholesterol from the body. This pathway of cholesterol elimination may explain the negative correlation which has been found between occurence of gallstone disease and levels of serum HDL, the preferred source of biliary cholesterol. Furthemore, production of crystallisation promoters limits stone growth, so that the small stones can still be expelled from the gallbladder together with floating crystals. Clearly, this attractive scheme is highly speculative, and much additional research is required to investigate these hypotheses further.
PERSPECTIVES
Biliary proteins do play a role in kinetics of cholesterol crystallisation particularly in the bile of patients with multiple gallstones. Research based on the classical concept of cholesterol nucleation promoters and inhibitors evaluating their individual role according to the criteria postulated by Harvey and Strasberg (157) led to the identification of a long list of putative important factors. However, none of these factors has been unequivocally linked to either cholesterol gallstone disease or to a subgroup of patients with multiple and rapidly developing gallstones in which the defect of nucleation should play a very important role. The failure of this classical approach can be explained by the fact that formation of bile is an extremely complex process under control of numerous genetic and environmental factors. The relative importance of the individual factors might thus be different between patients and/or groups of patients suffering from phenotypically the same gallstone disease. A rigorous genetic approach, q uantitative trait loci mapping for cholesterol gallstones, applied on gallstone resistant AKR/J and gallstone sensitive C57L/J mouse strains fed with lithogenic diet, has led to identification of an array of candidate Lith genes which seem to play a role in the disease, at least in mice (162, 163) . A similar approach based on gene linkage studies in carefully selected populations, in which environmental factors should be standardised as much as possible, is clearly required for successful analysis of the etiology of such a complex disease in humans. Understanding of the genes involved will probably lead to identification of the key players involved in the management of the lipid composition of bile and the most relevant regulator(s) of cholesterol crystallisation. Subsequent elucidation of the interaction with environmental factors may point the way to the development of novel strategies for the prevention of gallstone disease. 
